Showing 149,121 - 149,140 results of 226,199 for search '(( 5 ((step decrease) OR (mean decrease)) ) OR ( 10 ((nn decrease) OR (a decrease)) ))', query time: 2.32s Refine Results
  1. 149121

    Formation of <sup>1</sup>O<sub>2</sub> and H<sub>2</sub>O<sub>2</sub> during experiments in 2006, 2008 and 2009. by Stefanie P. Glaeser (542828)

    Published 2014
    “…A. 12<sup>nd</sup> July 2006: a clear sky during the afternoon led to a steady decrease in [<sup>1</sup>O<sub>2</sub>]<sub>SS</sub> concentrations from noon to late afternoon. …”
  2. 149122

    Prevention of skin flap necrosis in mice by EMSCs injection. by Chun-Chun Cheng (324809)

    Published 2013
    “…Data are presented as mean ± s.d. and analyzed with Student's <i>t</i>-test. …”
  3. 149123

    Pregnant SD and BN dams exhibit different susceptibility to alcohol in their thyroid function. by Laura J. Sittig (365827)

    Published 2013
    “…Alcohol-containing and calorie-restricted diets suppressed plasma TSH levels (F [2, 57] = 9.3, <i>P</i><0.01) and increased T3 (F [2, 58] = 4.0, <i>P</i> = 0.02) and fT3 (F [2, 49] = 5.6, <i>P</i><0.01) levels. Plasma fT4 was decreased by alcohol consumption in SD but not BN mothers (F [2, 56] = 5.5, <i>P</i><0.01). …”
  4. 149124

    Primary and secondary outcomes. by Axel Cosmus Pyndt Diederichsen (3134508)

    Published 2024
    “…<div><p>Background</p><p>The Danish cardiovascular screening (DANCAVAS) trial, a nationwide trial designed to investigate the impact of cardiovascular screening in men, did not decrease all-cause mortality, an outcome decided by the investigators. …”
  5. 149125

    Safety outcomes. by Axel Cosmus Pyndt Diederichsen (3134508)

    Published 2024
    “…<div><p>Background</p><p>The Danish cardiovascular screening (DANCAVAS) trial, a nationwide trial designed to investigate the impact of cardiovascular screening in men, did not decrease all-cause mortality, an outcome decided by the investigators. …”
  6. 149126

    Enrolment, randomisation, and follow-up. by Axel Cosmus Pyndt Diederichsen (3134508)

    Published 2024
    “…<div><p>Background</p><p>The Danish cardiovascular screening (DANCAVAS) trial, a nationwide trial designed to investigate the impact of cardiovascular screening in men, did not decrease all-cause mortality, an outcome decided by the investigators. …”
  7. 149127

    Generation, purification, and penetration of rISL1 protein. by Hananeh Fonoudi (278175)

    Published 2013
    “…<p>(A) Construction of the ISL1 protein expression vector in fusion with the TAT transduction domain for penetration into the cells and N-terminus histidine tag for purification of recombinant protein. …”
  8. 149128

    iNTS_QECH_2011-2019_aggregate_age.docx by Catherine Wilson (8586315)

    Published 2022
    “…Between 2011-2019 there was a substantial decrease in proportion of <i>S.</i> Typhimurium (78.5% to 27.7%) and <i>S. …”
  9. 149129
  10. 149130
  11. 149131
  12. 149132
  13. 149133
  14. 149134

    Table_1_Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus.docx by Limin Wang (87511)

    Published 2023
    “…</p>Clinical parameters<p>A significant decrease in fasting plasma glucose (8.22 ± 2.19 vs 6.87 ± 1.09 mmol/L), glycated serum protein [291.00 (264.00, 353.00) vs 275.00 (251.00, 342.50) μmol/L], hemoglobin A1c (7.39 ± 1.18 vs 7.12 ± 1.33%), body mass index (25.32 ± 2.99 vs 24.83 ± 2.95 kg/m<sup>2</sup>), systolic blood pressure (129.05 ± 17.51 vs 123.43 ± 14.82 mmHg), and urinary creatinine [158.40 (74.75, 219.15) vs 79.70 (56.25, 138.10) μmmol/kg] levels was noted after 30-day Cana monotherapy (P < 0.05).…”
  15. 149135

    DataSheet_1_Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus.xls by Limin Wang (87511)

    Published 2023
    “…</p>Clinical parameters<p>A significant decrease in fasting plasma glucose (8.22 ± 2.19 vs 6.87 ± 1.09 mmol/L), glycated serum protein [291.00 (264.00, 353.00) vs 275.00 (251.00, 342.50) μmol/L], hemoglobin A1c (7.39 ± 1.18 vs 7.12 ± 1.33%), body mass index (25.32 ± 2.99 vs 24.83 ± 2.95 kg/m<sup>2</sup>), systolic blood pressure (129.05 ± 17.51 vs 123.43 ± 14.82 mmHg), and urinary creatinine [158.40 (74.75, 219.15) vs 79.70 (56.25, 138.10) μmmol/kg] levels was noted after 30-day Cana monotherapy (P < 0.05).…”
  16. 149136

    DataSheet_3_Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus.xls by Limin Wang (87511)

    Published 2023
    “…</p>Clinical parameters<p>A significant decrease in fasting plasma glucose (8.22 ± 2.19 vs 6.87 ± 1.09 mmol/L), glycated serum protein [291.00 (264.00, 353.00) vs 275.00 (251.00, 342.50) μmol/L], hemoglobin A1c (7.39 ± 1.18 vs 7.12 ± 1.33%), body mass index (25.32 ± 2.99 vs 24.83 ± 2.95 kg/m<sup>2</sup>), systolic blood pressure (129.05 ± 17.51 vs 123.43 ± 14.82 mmHg), and urinary creatinine [158.40 (74.75, 219.15) vs 79.70 (56.25, 138.10) μmmol/kg] levels was noted after 30-day Cana monotherapy (P < 0.05).…”
  17. 149137

    DataSheet_2_Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus.xls by Limin Wang (87511)

    Published 2023
    “…</p>Clinical parameters<p>A significant decrease in fasting plasma glucose (8.22 ± 2.19 vs 6.87 ± 1.09 mmol/L), glycated serum protein [291.00 (264.00, 353.00) vs 275.00 (251.00, 342.50) μmol/L], hemoglobin A1c (7.39 ± 1.18 vs 7.12 ± 1.33%), body mass index (25.32 ± 2.99 vs 24.83 ± 2.95 kg/m<sup>2</sup>), systolic blood pressure (129.05 ± 17.51 vs 123.43 ± 14.82 mmHg), and urinary creatinine [158.40 (74.75, 219.15) vs 79.70 (56.25, 138.10) μmmol/kg] levels was noted after 30-day Cana monotherapy (P < 0.05).…”
  18. 149138
  19. 149139
  20. 149140